Monopar Therapeutics Inc.
NASDAQ:MNPRBiotechnology
+$1.58 today
- Market cap
- $479.46M
- Beta
- 1.54
- P/E (TTM)
- -37.6
- EPS (TTM)
- -$1.76
Volume 0.10M
Average 0.17M
MNPR Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Monopar Therapeutics Inc.NASDAQ: MNPR
Operating Expenses · Q1 FY2026 · quarter ended Mar 2026
Operating expenses growth accelerates
Q1 FY2026 operating expenses of $5.23M rose 62.2% year over year, ahead of the +5.9% change in trailing-twelve-month operating expenses. Sequentially, it fell 15.1% from the prior quarter. Over 3 fiscal years it compounded at +16.6% a year.
Context
- Operating expenses increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +62.2% holds above the trailing-twelve-month pace of +5.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 16.7M USD
- Year-over-year change
- +3.4%
- 4-year CAGR
- +16.3%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 16.7M | +3.4% |
| FY2024 | 2024-12-31 | 16.16M | +83.0% |
| FY2023 | 2023-12-31 | 8.83M | -16.2% |
| FY2022 | 2022-12-31 | 10.54M | +15.4% |
| FY2021 | 2021-12-31 | 9.13M | — |
Operating Expenses vs competitors
How MNPR compares with its peers on the latest reported figures
- Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +5.9% is the 6th highest of 11, against a peer median of +1.6%.
- Over three fiscal years its annual growth of +16.6% compares with a peer median of -1.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $299.94M USD | +54.6% | +80.8% | — | |
| LTM Jun 2026 | $261.54M USD | +14.7% | +83.3% | 249.1% | |
| LTM Mar 2026 | $234.87M USD | +104.1% | +34.7% | 369.9% | |
| LTM Sep 2026 | $217.29M USD | +5.9% | -11.0% | 81.7% | |
| LTM Mar 2026 | $190.31M USD | -2.8% | -18.0% | 240.4% | |
| LTM Mar 2026 | $173.51M USD | -10.6% | -12.1% | 110.5% | |
| LTM Mar 2026 | $91.02M USD | -33.2% | -6.5% | — | |
| LTM Mar 2026 | $74.43M USD | +18.8% | +19.7% | — | |
| FY2025 | €56.21M EUR | -12.4% | -3.9% | 2016.9% | |
| LTM Jun 2026 | $25.93M USD | -40.9% | +1.1% | 73.9% | |
| LTM Mar 2026 | $18.71M USD | +5.9% | +16.6% | — | |
| Peer median (excluding MNPR) | — | +1.6% | -1.4% | 240.4% | |
Competitors are the stored peer set for MNPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 6.49M | 7.59M | 5.6M | 13.01M | 9.9B |
| Selling, General & Admin | 2.63M | 2.95M | 3.23M | 3.16M | 6.8B |
| Operating Expenses | 9.13M | 10.54M | 8.83M | 16.16M | 16.7M |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 |
| EBITDA | (9.1M) | (10.52M) | (8.4M) | (15.59M) | (13.72M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (9.13M) | (10.54M) | (8.83M) | (16.16M) | (16.7M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 24.02K | 21.24K | 429.04K | 404.02K | 2.99M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 24.02K | 21.24K | 429.04K | 575.3K | 2.99M |
| Income Before Tax | (9.1M) | (10.52M) | (8.4M) | (15.59M) | (13.72M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (9.1M) | (10.52M) | (8.4M) | (15.59M) | (13.72M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.73) | (0.83) | (0.58) | (1.36) | (1.85) |
| EPS (Diluted) | (0.73) | (0.83) | (0.58) | (1.36) | (1.85) |
| Weighted Avg Shares | 12.47M | 12.72M | 14.51M | 11.44M | 7.41M |
| Weighted Avg Shares (Diluted) | 12.47M | 12.72M | 14.51M | 11.48M | 7.41M |
Monopar Therapeutics Inc.
NASDAQ:MNPR
Intrinsic Alpha fair value
Locked
Current Price
$70.75
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.